

IMMUNOMEDICS TO PRESENT AT 50th ASH ANNUAL MEETING

Morris Plains, NJ, December 2, 2008 - Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that seven presentations involving its potential products will be given at the 50th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6 - 9, 2008, in San Francisco, California. The schedule and meeting places for the presentations, together with the publication and board numbers are listed below:

- “Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody Immunotherapy” [Publication No. 1588, Session Name: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster I, Saturday, December 6, 5:30 p.m. – 7:30 p.m., Board # I-693, Moscone Center, Hall A]
- “A Novel Anti-CD20 IgG-Interferon-alpha2b Fusion Protein with Potent *in Vitro* and *in Vivo* Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method” [Publication No. 1590, Session Name: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster I, Saturday, December 6, 5:30 p.m. – 7:30 p.m., Board # I-695, Moscone Center, Hall A]
- “Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity” [Publication No. 1591, Session Name: Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents Poster I, Saturday, December 6, 5:30 p.m. – 7:30 p.m., Board # I-696, Moscone Center, Hall A]
- “Efficient Binding, but Moderate Modulation, of Human Dendritic Cell Functions by Milatuzumab, a Humanized Anti-CD74 Monoclonal Antibody” [Publication No. 2649, Session Name: Molecular Pharmacology, Drug Resistance Poster II, Sunday, December 7, 6:00 p.m. – 8:00 p.m., Board # II-743, Moscone Center, Hall A]
- “Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study” [Publication No. 3412, Session Name: Disorders of Platelet Number or Function Poster III, Monday, December 8, 5:30 p.m. – 7:30 p.m., Board # III-494, Moscone Center, Hall A]
- “First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma” [Publication No. 3697, Session Name: Myeloma - Therapy, excluding Transplantation Poster III, Monday, December 8, 5:30 p.m. – 7:30 p.m., Board # III-779, Moscone Center, Hall A]

- “Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has *in Vitro* and *in Vivo* Activity in Mantle Cell Lymphoma” [Publication No. 886, Session Name: Preclinical Studies in NHL: Novel Antibodies and Immunotherapeutic Approaches, Tuesday, December 9, 7:00 a.m. – 9:00 a.m., Oral presentation time 8:30 a.m., Moscone Center, 3006-3008 – West]

In addition, on Sunday December 7, from 8:00 p.m. – 9:30 p.m., the Company is hosting a Cocktail Reception at the Nob Hill A room of the San Francisco Marriott, where Dr. John Leonard of Weill Cornell Medical College and Dr. Jonathan Kaufman of Emory University School of Medicine will provide updates on epratuzumab, veltuzumab and milatuzumab.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 123 patents issued in the United States and more than 300 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at <http://www.immunomedics.com>. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:

Dr. Chau Cheng

Associate Director, Investor Relations & Business Analysis

(973) 605-8200, extension 123

ccheng@immunomedics.com